From: A retrospective study of cases diagnosed with cystic fibrosis at a single care center in Syria
N=85 | Two-class (IV/V) pathogenic variants N=9 | One-class (I) pathogenic variant + one-class (IV/V) pathogenic variant N=5 | *Two pathogenic variants of different classes of I, II, III N=6 | ** Two class II pathogenic variants N=10 | ***Two class II pathogenic variants N=36 | Two class I pathogenic variants N=19 |
---|---|---|---|---|---|---|
Mean age at diagnosis (months) | N=14 | N=71 | ||||
18.1±32.6 | 5.6±4.6 | 15.1±32.5 | 16.3±34.6 | 18.3±34.1 | 15±25.5 | |
Mortality | N=0 (0%) | N=1 (10%) | N=1 (16.7%) | N=4 (40%) | N=14 (38.9%) | N=6 (31.6%) |
N=1 (7.1%) | N=25 (35.2%) | |||||
Mean age at onset of gastrointestinal symptoms (months) | 5.6±10.3 | 1.2±1.8 | No symptoms | 9.7±18.8 | 2.2±2.3 | 1.2±1.6 |
Chronic diarrhea | N=4 (44.4%) | N=2 (40%) | N=0 (0%) | N=4 (40%) | N=14 (38.9%) | N=10 (52.6%) |
N=6 (42.8%) | N=28 (39.4%) | |||||
Meconium ileus | N=1 (11.1%) | N=1 (10%) | N=0 (0%) | N=5 (50%) | N=7 (19.4%) | N=9 (47.4%) |
N=2 (14.3%) | N=21 (29.6%) | |||||
Liver disease | N=1 (11.1%) | N=2 (40%) | N=1 (16.7%) | N=1 (10%) | N=10 (27.8%) | N=7 (36.8%) |
N=3 (21.4%) | N=19 (26.8%) | |||||
Steatorrhea | N=1 (11.1%) | N=0 (0%) | N=0 (0%) | N=3 (30%) | N=11 (30.5%) | N=13 (68.4%) |
N=1 (7.1%) | N=27 (38%) | |||||
Mean age at onset of respiratory disease (months) | 7.2±9.3 | 4.9±4.4 | 5.7±6 | 3±2.1 | 2.9±2.3 | 15±26 |
Recurrent respiratory infections | N=2 (22.2%) | N=3 (60%) | N=3 (50%) | N=4 (40%) | N=15 (41.7%) | N=6 (31.6%) |
N=5 (35.7%) | N=28 (39.4%) | |||||
Bronchitis | N=2 (22.2%) | N=2 (20%) | N=1 (16.7%) | N=6 (60%) | N=8 (22.2%) | N=7 (36.8%) |
N=4 (28.6%) | N=22 (31%) | |||||
Failure to thrive | N=5 (55.5%) | N=2 (40%) | N=3 (50%) | N=6 (60%) | N=20 (55.5%) | N=13 (68.4%) |
N=7 (50%) | N=42 (59.1%) | |||||
The average length of hospital stay | 17.7±11.8 | 10.2±9.9 | 14±9 | 13.2±3.3 | 19±14.1 | 16.3±9.7 |